2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - R02-R05
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MPN, CML, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human
PAPER

1076 Implementation of home blood transfusions for patients with hematologic malignancies and bone marrow failure syndromes

Adam Binder, MD, Gina Keiffer, MD2, Chetan Jeurkar, DO3, Kathryn Yingling, NP4, Byron Lu, MD5, Kaitlin Rancani, NP6, Amanda Doy7, Julianna Lenoir8, Alexandra Cohen, MD9, Julie Karp, MD10, Juliana Guarente11, Casey Degen, MD12, Angelica Vivero, MD13, Margaret Kasner, MD14, Kristin Rising, MD15, Lindsay Wilde, MD16
1 Thomas Jefferson University, Philadelphia, United States
2 Thomas Jefferson University, Philadelphia, United States
3 Thomas Jefferson University, Philadelphia, United States
4 Thomas Jefferson University, Philadelphia, United States
5 Thomas Jefferson University, Philadelphia, United States
6 Thomas Jefferson University, Philadelphia, United States
7 Thomas Jefferson University, Philadelphia, United States
8 Thomas Jefferson University, Philadelphia, United States
9 Thomas Jefferson University, Philadelphia, United States
10 Thomas Jefferson University, Philadelphia, United States
11 Thomas Jefferson University, Philadelphia, United States
12 Thomas Jefferson University, Philadelphia, United States
13 Thomas Jefferson University, Philadelphia, United States
14 Thomas Jefferson University, Philadelphia, United States
15 Thomas Jefferson University, Philadelphia, United States
16 Thomas Jefferson University, Philadelphia, United States

Introduction:

Patients with hematologic malignancies (HM) or bone marrow failure syndromes are often dependent on red blood cell (RBC) and/or platelet (PLT) transfusions due to disease or therapy related cytopenias. This includes about 50% of patients with low-risk myelodysplastic syndrome (MDS) within 6 months of diagnosis, up to 40% of patients with acute myeloid leukemia (AML) at diagnosis, and almost 100% of patients AML during AML treatment. This creates a large burden on patients and caregivers.

In the US, blood products are transfused at a healthcare facility. Recent research has evaluated the role of home transfusions in patients with HM near the end of life or under hospice care, but not throughout the care continuum. Data from a prior qualitative study demonstrated that patients treated with curative intent are interested in and would likely benefit from home transfusions. This pilot study implemented and evaluated a home transfusion program for patients with transfusion-dependent HM.

Methods:

This is a single arm implementation study to evaluate a home transfusion program. Eligiblity criteria include: have a diagnosis of a HM or bone marrow failure syndrome, require 2 or more transfusions in a 28-day period, live within 30 miles of the cancer center and have reliable internet. Individuals are excluded if they have New York Heart Association class II-IV heart failure, history of a transfusion reaction other than a febrile non-hemolytic transfusion reaction, require HLA matched PLTs or have RBC antibodies. Participants have blood drawn and receive transfusions, if needed, on the same day. Up to 1 home transfusion encounter per week and a total of 5 home transfusion encounters are allowed during study participation. The home transfusion process follows our infusion center protocol. At the end of the study, Feasibility, Acceptability and Appropriateness surveys as well as qualitative interviews are completed.

Results:

19 participants enrolled in the study from June 2025 to July 2026. Median age is 74 (range: 27-90), 8 (42.1%) identify as female, 3 (15.8%) black/African American, 4 (21.1%) Hispanic/Latinx, 13 (68.4%) white. 14 (74%) have a diagnosis of AML or MDS. 4 participants became ineligible prior to transfusion (2 transitioned to hospice, 2 became transfusion independent). 15 participants received home transfusions, with 11 (73%) on therapy at the time of transfusion and 4 of 11 (37%) of these having curative intent.

62 home visits occurred with 61 successful blood draws. 1 blood draw did not occur due to a medical emergency unrelated to the study protocol.  There were no issues with delivery or processing of labs. 40 transfusion events occurred; 14 PLT only, 17 RBC only, 9 both PLT and RBC. Median PLT count was 13 (IQR: 8-15), median hemoglobin was 7.1 (IQR: 6.7-7.8). There were no issues with packaging or transporting blood products. Nurses scanned blood products and recorded vital signs and blood product administration in the electronic health record. One transfusion was not completed due to a febrile non-hemolytic transfusion reaction; the transfusion reaction protocol was followed. That participant received subsequent home transfusions with pre-medications without incident. No other adverse events were reported.

12 of 15 participants were surveyed and interviewed. 100% of participants agreed that home transfusions were feasible. 11 (93.3%) participants agreed the program was acceptable and appropriate, and 1 participant did not think the program was right for him due to concerns about transfusion reactions at home. Most felt the home transfusion model was convenient, saved time, and was comfortable. Home transfusions reduced patient transportation costs and provided flexibility in their day. Most participants felt the program was too short.

Conclusion:

Home blood transfusions within the US healthcare infrastructure are safe, feasible and acceptable. There were no unexpected logistical barriers or safety concerns. Most participants appreciated the program and wanted continued services, suggesting support for implementation of similar programs as the standard of care. Home transfusions have potential to significantly reduce burden of care for patients. We have ongoing work evaluating the financial implications of home transfusions and potential collaborations with payors to analyze cost implications of scaling this model across multiple health systems.

Adam Binder, MD: karyopharm - Honoraria; Johnson and Johnson - Honoraria; Regeneron - Research Funding; Johnson and Johnson - Research Funding; Sanofi - Research Funding; Bristol Myers Squibb - Research Funding